Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy
Cancer Reports · 2024
DOI: 10.1002/cnr2.1960 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Satoru Hagiwara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors have been reported to have excellent therapeutic effects on various malignant tumors. However, immune‐related adverse events can occur, targeting various organs. Case presentation A 49‐year‐old male with lung carcinoma was started on carboplatin + pemetrexed + nivolumab (every 3 weeks) + ipilimumab (every 6 weeks), and nivolumab/ipilimumab was administered in the 3rd course. Subsequently, fever and fatigue developed, and grade 3 liver damage was also noted, so he was admitted to Kindai University Hospital. A bone marrow aspirate examination was performed on the third day of illness, and a definitive diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made. It was determined that immediate therapeutic intervention was necessary, and pulse therapy with methylprednisolone was started on the third day of illness. After 3 days of pulse treatment, a rapid recovery of platelet values, a decrease in ferritin levels, and a decrease in lactate dehydrogenase were observed. Subjective symptoms such as fever and fatigue also quickly improved.
Conclusion
Early diagnosis and treatment for HLH resulted in a positive response. The number of HLH cases may increase in the future due to the expansion of immune checkpoint inhibitor indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
ORCID-Profile: Satoru Hagiwara
Zitieren
APA
Hagiwara, S., Tanizaki, J., Hayashi, H., Komeda, Y., Nishida, N., Yoshida, A., Yamamoto, T., Matsubara, T., & Kudo, M. (2024). Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. Cancer Reports. https://doi.org/10.1002/cnr2.1960
Vancouver
Hagiwara S, Tanizaki J, Hayashi H, Komeda Y, Nishida N, Yoshida A, et al. Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. Cancer Reports. 2024. doi:10.1002/cnr2.1960
BibTeX
@article{Hagiwara2024,
author = {Hagiwara, Satoru and Tanizaki, Junko and Hayashi, Hidetoshi and Komeda, Yoriaki and Nishida, Naoshi and Yoshida, Akihiro and Yamamoto, Tomoki and Matsubara, Takuya and Kudo, Masatoshi},
title = {Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.1960}
}
EUVIMED